As President Trump prepares to unveil a major tariff plan, pharmaceutical companies are lobbying for a gradual implementation to mitigate the impact on drug prices and supply. With potential tariffs looming, how will the industry adapt?
Eli Lilly is set to unveil results from trials of orforglipron, its groundbreaking once-daily obesity pill, potentially revolutionizing weight loss treatment by offering a needle-free alternative. Analysts predict it could capture a significant share of the $150 billion GLP-1 market.
Eli Lilly to invest $27 billion in building new US manufacturing plants amid challenges from drug import duties. The move aligns with Trump's push for American manufacturing revitalization.
